18 Papers
25 Citations
Bing Xia is an academic researcher from Tianjin Medical University Cancer Institute and Hospital. The author has contributed to research in topics: Diffuse large B-cell lymphoma & Medicine. The author has an hindex of 8, co-authored 18 publications.
Chat about Author
Papers
c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia
Bing Xia,Chen Tian,Shanqi Guo,Le Zhang,Dandan Zhao,Fulian Qu,Weipeng Zhao,Yafei Wang,Xiaoxiong Wu,Wanming Da,Sheng Wei,Yizhuo Zhang +11 more
TL;DR: It is reported that mesenchymal stromal cells (MSC) are essential component of bone marrow microenvironment which affects the survival of AML cells and c-Myc is a potential therapeutic target for overcoming drug resistance in AML.
81
High prevalence of hepatitis B virus infection in patients with aggressive B cell non-Hodgkin's lymphoma in China.
Chaoyu Wang,Bing Xia,Qiaoyang Ning,Haifeng Zhao,Hongliang Yang,Zhigang Zhao,Xiaofang Wang,Yafei Wang,Yong Yu,Yizhuo Zhang +9 more
TL;DR: HBV seems to have a very important role in the pathogenesis of aggressive B-NHL in China, where HBV is endemic and infection was significantly associated with increased risks for aggressive B -NHL.
36
Gene expression profiles analysis identifies a novel two-gene signature to predict overall survival in diffuse large B-cell lymphoma
TL;DR: A set of novel genes and pathways that may play a significant role in the initiation and progression of DLBCL are identified and CDC20 and PTGDS will provide useful guidance for therapeutic applications.
Potential Therapeutic Roles of Exosomes in Multiple Myeloma: A Systematic Review.
TL;DR: A more rigorous investigation into exosomes will pave the way for novel tumor therapies in MM patients, as the natural nano structure of exosome makes them excellent carriers for drug delivery.
Overexpression of DNA methyltransferase 1 as a negative independent prognostic factor in primary gastrointestinal diffuse large B-cell lymphoma treated with CHOP-like regimen and rituximab.
TL;DR: DNMT1 was identified to be an independent prognostic factor for predicting the survival and progression-free survival of patients with PGI-DLBCL; this suggests that it could be used as a marker to indicate the prognosis of P GI- DLBCL.